Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)
Montreal Heart Institute
2,570 participants
Mar 3, 2026
INTERVENTIONAL
Conditions
Summary
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Eligibility
Inclusion Criteria6
- Age ≥18 years;
- Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
- Coronary angiogram performed;
- Planned for medical management alone, without revascularization;
- Willingness to participate and to attend study visits;
- Expected life expectancy ≥12 months.
Exclusion Criteria10
- Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
- Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
- Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
- Confirmed or suspected spontaneous coronary artery dissection;
- Concomitant indication for chronic oral anticoagulant;
- Concomitant non-coronary indication for dual antiplatelet therapy;
- Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
- Previous hospitalization for MI, PCI, or CABG within 12 months;
- Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
- Unsuitability for either randomization treatment, based on the judgement of the treating physician
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ticagrelor 90 mg twice daily + placebo once daily
Ticagrelor 90 mg twice daily + aspirin 80 mg once daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07257198